Buprenorphine/naloxone access for people with opioid use disorder in correctional facilities: taking steps to support knowledge translation

Health & Justice

Lori Kiefer¹  Marina Sadik²  Claire Bodkin²  Dale Guenter²  Lori Regenstreif²  Erin Beaulieu²  Fiona G. Kouyoumdjian²  Patsy W. P. Lee³ 

[1] Dalla Lana School of Public Health, University of Toronto;Department of Family Medicine, McMaster University;Michael G. DeGroote School of Medicine, McMaster University;

关键词: Opioid use disorder;    Opioid agonist treatment;    Buprenorphine;    Correctional facility;    Prison;    Jail;   

DOI  :  10.1186/s40352-022-00174-w

来源: DOAJ

【 摘 要 】

Abstract People with opioid use disorders are overrepresented in correctional facilities, and are at high risk of opioid overdose. Despite the fact that buprenorphine/naloxone is the first line treatment for people with opioid use disorder, there are often institutional, clinical, and logistical barriers to buprenorphine/naloxone initiation in correctional facilities. Guided by the knowledge-to-action framework, this knowledge translation project focused on synthesizing knowledge and developing a tool for buprenorphine/naloxone initiation that was tailored to correctional facilities, including jails. This information and tool can be used to support buprenorphine/naloxone access for people in correctional facilities, in parallel with other efforts to address barriers to treatment initiation in correctional facilities.

【 授权许可】

Unknown